Updates to Medicare Advantage and the Part D Prescription Drug program will improve programs for health plans that provide care for vulnerable enrollees.
Updates to Medicare Advantage and the Part D Prescription Drug program will improve programs for health plans that provide care for vulnerable enrollees. The finalized payment and policy changes for 2017 also seek to provide table payments to plans.
The final updates have incorporated feedback received during the public comment period after the policies were first proposed in February.
“We continue to strengthen Medicare Advantage and Medicare Part D, in particular for enrollees who need additional investments in their health…” Acting Administrator Andy Slavitt said in a statement. “With these polices, we will continue to see improvements in growth, affordability, benefits, and quality for millions of seniors and people living with disabilities.”
These new updates will are expected to improve the accuracy of payments to MA plans, including a new methodology that should better reflect the cost of care, and the socioeconomic and disability status of the enrollee, in addition to increasing stability for the program within Puerto Rico.
The anticipated revenue change is approximately 0.85%, not counting the typical 2.2% added in from the growth in coding acuity. This is somewhat smaller than the first estimate in the February Advance Notice due to technical updates in the risk adjustment normalization factor.
CMS policies are also being finalized for discouraging opioid overutilization.
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More